Synthetic biology stands at the threshold of transformative breakthroughs that will reshape medicine, agriculture, manufacturing, and our relationship with the natural world. As we look toward 2026-2035, convergence of artificial intelligence, automation, advanced gene editing, and systems biology promises to accelerate innovation while raising profound questions about how humanity should wield these powerful capabilities. This chapter explores emerging technologies, projected applications, challenges to overcome, and the vision of synthetic biology serving all humanity guided by the principle of 弘益人間 (Hongik Ingan)—Benefit All Humanity.
Just as ChatGPT and other large language models transformed natural language processing, foundation models trained on biological data are revolutionizing synthetic biology design:
AlphaFold and Protein Structure Prediction: Google DeepMind's AlphaFold (2020-2024) accurately predicts 3D protein structures from amino acid sequences, solving a 50-year grand challenge. AlphaFold 3 (2024) predicts protein-DNA, protein-RNA, and protein-ligand interactions, enabling rational drug design.
ESM (Evolutionary Scale Modeling): Meta AI's protein language model trained on 250+ million protein sequences generates novel functional proteins with no natural homologs.
CRISPR-GPT (Stanford 2025): Predicts optimal guide RNA sequences, off-target effects, and repair outcomes, reducing experimental design time from months to days.
Emerging: Whole-Genome Design Models: Future models will design entire genomes optimized for specific functions (e.g., maximal biofuel production, minimal metabolic burden).
AI enables closing the loop between computational design and experimental validation:
Ginkgo Bioworks' Foundries (2025): Operate automated design-build-test facilities processing 100,000+ genetic designs annually, iterating designs at unprecedented speed.
Impact: Design cycles that previously required years now complete in weeks; enables engineering of complex multi-gene systems previously intractable.
Generative AI creates novel biological sequences not found in nature:
Challenge: Ensuring AI-designed biological entities are safe; developing screening protocols for computationally-designed organisms.
Prime Editing 2.0: Enhanced prime editors achieve >95% editing efficiency with expanded sequence targeting (currently limited to ~50% efficiency). Enable precise installation of large insertions (100+ bp) for gene therapy applications.
Epigenetic Editors: Reversible, tunable gene expression control without DNA cutting. dCas9 fused to epigenetic modifiers (DNA methyltransferases, histone acetyltransferases) create heritable on/off switches for therapeutic genes.
RNA Editing: Cas13-based RNA editors precisely modify RNA transcripts without genomic changes. Applications: temporary gene expression modification, RNA virus engineering, mRNA therapeutics.
Multiplexed Editing: Simultaneous editing of 10-20 genomic loci in single intervention. Enable comprehensive rewiring of cellular pathways for complex disease treatment and metabolic engineering.
In Vivo Delivery Breakthroughs: Lipid nanoparticles, exosomes, and engineered viral vectors enable efficient delivery to previously inaccessible tissues (brain, muscle, solid tumors).
Yeast Genome Project (Sc2.0) demonstrates feasibility of designing and constructing synthetic eukaryotic chromosomes:
Applications: Chassis organisms optimized for industrial production; organisms resistant to all viruses (no natural genetic code compatibility); xenobiology (organisms biochemically isolated from natural life).
Future cell therapies will function as living therapeutics with programmable logic:
Combining synthetic biology with tissue engineering creates living replacement organs:
Insulin-Producing Organoids: Vertex/CRISPR Therapeutics developing edited stem cells differentiated into insulin-producing islet clusters for Type 1 diabetes; Phase 1/2 trials ongoing (2025-2026).
Bioengineered Organs: Growing transplantable organs from patient cells using decellularized scaffolds seeded with engineered cells; xenotransplantation using genetically modified pigs.
Blood-Brain Barrier Models: Engineered organoids mimicking BBB for drug testing; accelerates CNS drug development.
Synthetic Meat: Cultured meat grown from animal cells without animal slaughter; companies like Upside Foods, Eat Just receive regulatory approval (USA 2023); cost decreasing toward price parity with conventional meat by 2030.
Synthetic biology addresses climate crisis through multiple pathways:
PFAS Degradation: Engineered bacteria break down "forever chemicals" (PFAS) contaminating water supplies; field trials begin 2027-2028.
Microplastic Capture: Genetically modified organisms producing sticky biofilms that capture microplastics from marine environments; deployment in ocean gyres and wastewater treatment plants.
Heavy Metal Remediation: Hyperaccumulator plants engineered for enhanced metal uptake; combined with microbial metallophores concentrating metals for recovery.
Oil Spill Response: Engineered marine bacteria rapidly degrade petroleum hydrocarbons; deployable within hours of spill detection.
Concrete Carbon Capture: Bacteria incorporated into concrete formulations capture CO₂ during curing, creating carbon-negative building materials; commercialization by 2028.
By 2035, synthetic biology could produce 30-40% of physical materials currently derived from petroleum:
Animal agriculture accounts for 15-18% of global greenhouse gas emissions. Cellular agriculture offers alternative:
Medicine: Gene therapies treating 50+ genetic diseases, available globally through tiered pricing and local manufacturing; cancer immunotherapies achieving 60-70% cure rates; regenerative medicine providing bioengineered organs eliminating transplant waiting lists.
Agriculture: Climate-resilient crops feeding growing population despite climate change; 40% reduction in fertilizer/pesticide use through engineered microbiomes; vertical farms using engineered plants providing local food production in cities.
Environment: Atmospheric CO₂ stabilizing as enhanced photosynthesis and carbon capture scale globally; ocean plastic accumulation declining through microbial degradation; PFAS contamination remediated in major water supplies.
Manufacturing: 35% of materials bio-based, reducing petroleum dependence; cellular agriculture providing sustainable protein for 2 billion people; carbon-negative building materials standard in new construction.
Global Equity: Technology transfer enabling local production in 50+ countries; tiered pricing ensuring $2M therapies accessible in low-resource settings; capacity building creating synthetic biology expertise globally.
Governance: International frameworks balancing innovation with safety; inclusive governance incorporating diverse voices; transparent oversight preventing malicious misuse while enabling beneficial research.
2026-2027:
2028-2030:
2031-2035:
Realizing synthetic biology's potential while avoiding catastrophic risks requires adhering to core principles:
The 21st century may be remembered as the "Biological Century"—when humanity learned to read, write, and ultimately design the language of life. Synthetic biology promises transformative benefits: curing genetic diseases, feeding a growing population sustainably, reversing environmental degradation, manufacturing without petroleum, and unlocking biological innovations impossible in nature.
Realizing this vision requires overcoming formidable technical challenges (complexity, predictability, scale-up), economic barriers (development costs, competitiveness), and social obstacles (regulatory frameworks, public acceptance, equitable access). Most fundamentally, it requires ethical commitment to developing synthetic biology as a tool serving all humanity—not just the wealthy and powerful—guided by principles of equity, environmental stewardship, inclusive governance, and ongoing humility about the limits of human foresight.
The convergence of AI, automation, and advanced gene editing accelerates synthetic biology's progress, potentially compressing decades of anticipated breakthroughs into a few transformative years (2026-2035). Whether this biological revolution benefits all humanity or exacerbates inequality depends on choices we make today about governance, access, and values. The WIA-SYNTHETIC-BIOLOGY standard calls upon researchers, policymakers, companies, and citizens to ensure synthetic biology fulfills its promise of 弘익人間—Benefiting All Humanity.